Isabel Illa

List of Publications by Year
in descending order

81 papers	6,692 citations	101543 36 h-index	64796 79 g-index
86 all docs	86 docs citations	86 times ranked	5483 citing authors

#	Article	IF	Citations
1	Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nature Genetics, 1998, 20, 31-36.	21.4	857
2	International consensus guidance for management of myasthenia gravis. Neurology, 2016, 87, 419-425.	1.1	736
3	Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology, 2001, 50, 195-201.	5.3	577
4	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
5	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	236
6	Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e149.	6.0	205
7	Regional variation of Guillain-BarrÃ© syndrome. Brain, 2018, 141, 2866-2877.	7.6	190
8	Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nature Reviews Neurology, 2017, 13, 533-547.	10.1	188
9	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018, 141, 1609-1621.	7.6	169
10	Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain, 2017, 140, 1851-1858.	7.6	167
11	Acute axonal Guillain-BarrÃ© syndrome with IgG antibodies against motor axons following parenteral gangliosides. Annals of Neurology, 1995, 38, 218-224.	5.3	166
12	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
13	Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Annals of Neurology, 1998, 44, 976-980.	5.3	140
14	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain, 2015, 138, 2847-2858.	7.6	128
15	Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain, 2016, 139, 1700-1712.	7.6	111
16	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences, 2020, 412, 116803.	0.6	110
17	Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. Journal of Neuroimmunology, 2008, 201-202, 90-94.	2.3	108
18	Cortactin autoantibodies in myasthenia gravis. Autoimmunity Reviews, 2014, 13, 1003-1007.	5.8	93

#	Article	IF	Citations
19	Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurology, 2016, 73, 1099.	9.0	90
20	Absence of Dysferlin Alters Myogenin Expression and Delays Human Muscle Differentiation â€œin Vitroâ€• Journal of Biological Chemistry, 2006, 281, 17092-17098.	3.4	88
21	Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology, 2020, 94, e1171-e1180.	1.1	88
22	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	10.2	85
23	Fulminant Guillain-Barrï¿½ Syndrome with universal inexcitability of peripheral nerves: A clinicopathological study. , 1997, 20, 846-857.		81
24	Muscle MRI in muscular dystrophies. Acta Myologica, 2015, 34, 95-108.	1.5	73
25	Antiâ€“neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo. Journal of Clinical Investigation, 2019, 129, 2222-2236.	8.2	68
26	Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Scientific Reports, 2017, 7, 14411.	3.3	62
27	Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity. Journal of Neuroimmunology, 2016, 291, 82-88.	2.3	59
28	Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. Journal of Neuroinflammation, 2017, 14, 224.	7.2	50
29	Cathepsins Are Upregulated by IFN-Î³/STAT1 in Human Muscle Culture: A Possible Active Factor in Dermatomyositis. Journal of Neuropathology and Experimental Neurology, 2001, 60, 847-855.	1.7	49
30	Dysferlin Regulates Cell Adhesion in Human Monocytes. Journal of Biological Chemistry, 2013, 288, 14147-14157.	3.4	49
31	Peripheral Neuropathy Associated with Anti-GM2 Ganglioside Antibodies: Clinical and Immunopathological Studies. Autoimmunity, 2000, 32, 133-144.	2.6	46
32	Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy. Brain, 2021, 144, 1183-1196.	7.6	46
33	New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain, 2020, 143, 2696-2708.	7.6	45
34	Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. Neurology, 2020, 94, e1094-e1102.	1.1	45
35	Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study. Scientific Reports, 2018, 8, 10898.	3.3	44
36	Muscle imaging in muscle dystrophies produced by mutations in the EMD and LMNA genes. Neuromuscular Disorders, 2016, 26, 33-40.	0.6	40

#	Article	IF	Citations
37	Serum neurofilament light chain predicts long-term prognosis in Guillain-BarrÃ© syndrome patients. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 70-77.	1.9	40
38	Clinical characteristics and outcomes of thymomaâ€associated myasthenia gravis. European Journal of Neurology, 2021, 28, 2083-2091.	3.3	39
39	Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 576-585.	1.9	38
40	Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy. Cell Death and Disease, 2018, 9, 776.	6.3	36
41	Genotypeâ€“phenotype correlations in recessive titinopathies. Genetics in Medicine, 2020, 22, 2029-2040.	2.4	35
42	Analysis of Serum miRNA Profiles of Myasthenia Gravis Patients. PLoS ONE, 2014, 9, e91927.	2.5	35
43	RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis. Arthritis Research and Therapy, 2017, 19, 174.	3.5	34
44	Role of Thrombospondin 1 in Macrophage Inflammation in Dysferlin Myopathy. Journal of Neuropathology and Experimental Neurology, 2010, 69, 643-653.	1.7	33
45	Platelet-Derived Growth Factor BB Influences Muscle Regeneration in Duchenne Muscle Dystrophy. American Journal of Pathology, 2017, 187, 1814-1827.	3.8	33
46	Hypoxia triggers IFN-I production in muscle: Implications in dermatomyositis. Scientific Reports, 2017, 7, 8595.	3.3	30
47	Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	30
48	Expression of Poliovirus Receptor in Human Spinal Cord and Muscle. Annals of the New York Academy of Sciences, 2006, 753, 48-57.	3.8	29
49	Diagnostic utility of cortactin antibodies in myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1412, 90-94.	3.8	26
50	Caveats and Pitfalls of SOX1 Autoantibody Testing With a Commercial Line Blot Assay in Paraneoplastic Neurological Investigations. Frontiers in Immunology, 2019, 10, 769.	4.8	26
51	IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status. Journal of Neurology, 2005, 252, i14-i18.	3.6	25
52	Followâ€up of lateâ€onset Pompe disease patients with muscle magnetic resonance imaging reveals increase in fat replacement in skeletal muscles. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1032-1046.	7.3	25
53	Predicting Outcome in Guillain-BarrÃ© Syndrome. Neurology, 2022, 98, .	1.1	22
54	Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. Scientific Reports, 2019, 9, 6155.	3.3	20

#	Article	IF	Citations
55	Identification of serum microRNAs as potential biomarkers in Pompe disease. Annals of Clinical and Translational Neurology, 2019, 6, 1214-1224.	3.7	19
56	Autoantibody screening in Guillainâ€“BarrÃ© syndrome. Journal of Neuroinflammation, 2021, 18, 251.	7.2	19
57	Early diagnosis of amyotrophic lateral sclerosis mimic syndromes: pros and cons of current clinical diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 333-340.	1.7	17
58	Amyotrophic lateral sclerosis: A higher than expected incidence in people over 80 years of age. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 522-527.	1.7	15
59	A new mutation of the SCGA gene is the cause of a late onset mild phenotype limb girdle muscular dystrophy type 2D with axial involvement. Neuromuscular Disorders, 2018, 28, 633-638.	0.6	15
60	Drugâ€refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Annals of Clinical and Translational Neurology, 2022, 9, 122-131.	3.7	13
61	Thrombospondin-1 mediates muscle damage in brachio-cervical inflammatory myopathy and systemic sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	12
62	Antiganglioside Antibodies in Patients with Acute Polio and Post-Polio Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 374-377.	3.8	11
63	ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of autoâ€immunity to nodal components. Journal of the Peripheral Nervous System, 2017, 22, 418-424.	3.1	10
64	Registro espaÃ±ol de la enfermedad de Pompe: anÃ¡lisis de los primeros 49 pacientes con enfermedad de Pompe del adulto. Medicina ClÃnica, 2020, 154, 80-85.	0.6	9
65	Bethlem Myopathy Phenotypes and Follow Up: Description of 8 Patients at the Mildest End of the Spectrum. Journal of Neuromuscular Diseases, 2016, 3, 267-274.	2.6	7
66	Myasthenia Gravis Treatment Updates. Current Treatment Options in Neurology, 2020, 22, 1.	1.8	7
67	Late onset Sandhoff disease presenting with lower motor neuron disease and stuttering. Neuromuscular Disorders, 2021, 31, 769-772.	0.6	6
68	Effect of MAPK Inhibition on the Differentiation of a Rhabdomyosarcoma Cell Line Combined With CRISPR/Cas9 Technology: An In Vitro Model of Human Muscle Diseases. Journal of Neuropathology and Experimental Neurology, 2018, 77, 964-972.	1.7	5
69	Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT. Molecular Genetics and Metabolism, 2019, 128, 129-136.	1.1	5
70	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	1.5	4
71	Distal anterior compartment myopathy: A dysferlin mutation causing a new muscular dystrophy phenotype. Annals of Neurology, 2001, 49, 130-134.	5.3	4
72	Severe exacerbation of Andersenâ€“Tawil syndrome secondary to thyrotoxicosis. Journal of Human Genetics, 2014, 59, 465-466.	2.3	3

#	Article	IF	Citations
73	McLeod syndrome is a new cause of axial muscle weakness. Muscle and Nerve, 2018, 58, E5.	2.2	3
74	Proteasome inhibitors reduce thrombospondin-1 release in human dysferlin-deficient myotubes. BMC Musculoskeletal Disorders, 2020, 21, 784.	1.9	3
75	Platelet Derived Growth Factor-AA Correlates With Muscle Function Tests and Quantitative Muscle Magnetic Resonance in Dystrophinopathies. Frontiers in Neurology, 2021, 12, 659922.	2.4	3
76	Isolation of human fibroadipogenic progenitors and satellite cells from frozen muscle biopsies. FASEB Journal, 2021, 35, e21819.	0.5	3
77	Absence of pathogenic mutations in CD59 in chronic inflammatory demyelinating polyradiculoneuropathy. PLoS ONE, 2019, 14, e0212647.	2.5	2
78	Transthyretin-related hereditary amyloid polyneuropathy presenting with large fibre involvement and cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2016, 23, 64-65.	3.0	1
79	Comment to â€œRole of Toll-like receptors and retinoic acid inducible gene I in endogenous production of type I interferon in dermatomyositisâ€. Journal of Neuroimmunology, 2016, 291, 125.	2.3	1
80	Sustained Complete Metabolic Remission After Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE).. Blood, 2009, 114, 1181-1181.	1.4	1
81	Comment to â€œAutoantibodies to cortactin and agrin in sera of patients with myasthenia gravisâ€. Journal of Neuroimmunology, 2021, 358, 577659.	2.3	0